GI Motility · Capsule Diagnostics · Point of Care

Precision Gastric Motility –
Anywhere,
Safe & Simple

GastricTime replaces complex hospital-bound motility tests with a radiation-free, battery-free swallowable capsule
and wearable reader – delivering actionable motility data at the point of care.

Explore Partnership
$100B+GLP-1 market driving new diagnostic demand
40M+Americans with GI motility symptoms
~1 in 75patients with delayed gastric emptying ever formally diagnosed
The Unmet Need

A Critical Clinical Variable
Missing From Routine Care

Gastric motility disorders affect millions worldwide – yet objective measurement remains absent from routine care. The rapid adoption of GLP-1 receptor agonists has made this diagnostic gap more consequential than ever.

The Clinical Blindspot

Clinicians Are Making High-Stakes Decisions Without Data

When GI symptoms arise, clinicians cannot objectively distinguish drug-induced motility changes from underlying pathology. Without that data, patients face an impossible tradeoff – abandoning treatments that may still be right for them, or continuing without knowing whether genuine gastroparesis is present.

The Broad Context

Gastric Motility Is a Critical Variable Across Metabolic Care

From determining insulin timing in personalized diabetes management, to evaluating candidates for bariatric surgery and monitoring outcomes post-procedure – objective gastric emptying data is needed across multiple high-stakes clinical decisions. Today, it is routinely absent.

The current gold standard is not underused because it’s unnecessary – but because it’s inaccessible.

Current Gold Standard: Scintigraphy

  • ×Hospital-bound – requires nuclear medicine facilities
  • ×Radioactive meal required for imaging
  • ×$1,200 per test – facility-based cost
  • ×4–6 hour sessions – impractical for repeat testing
  • ×Requires specialized imaging staff

Consequence: Untreated Diagnostic Gap

  • !Premature GLP-1 discontinuation despite potential benefit
  • !Inappropriate dose escalation or reduction
  • !Unnecessary referrals, imaging, or drug switching
  • !Lost therapeutic value in high-cost treatments
  • !Risk of aspiration in undiagnosed gastroparesis patients
The Technology

Simple Measurement,
Actionable Insight

A swallowable capsule dissolves in the stomach, releasing passive RFID tags that are individually detected as they transit the pylorus – no batteries, no radiation, no hospital required.

1

Wearable Reader Placement

Step 1
2

Capsule & Meal Ingestion

Step 2
3

Intragastric Tag Dispersion

Step 3
4

Precision Pyloric Detection

Step 4
5

AI-Powered Clinical Output

Step 5
GastricTime demo video
Watch the GastricTime Demo
Patent Pending

US Provisional Patent Application No. 63/837,170

Competitive Advantage

Cost, Simplicity, and
Repeatability at Scale

GastricTime is designed not to replace the specialist – but to bring objective motility measurement into every care setting.

AttributeScintigraphyWireless Motility CapsuleGastricTime
Radiation & Toxicity× Radioactive× Ingested Battery
Passive RFID – no radiation, no battery
Cost× Expensive× Expensive
Affordable
Test Setting× Hospital / Nuclear medicine Specialty GI center
Primary care / Outpatient
Test Duration 4–6 hours imaging× 8–48 hours total
2–4 hours gastric-specific
The Team

Built by Those Who Have
Done It Before

GastricTime was founded by veterans of the MedTech industry – with decades of combined experience developing and commercializing GI innovations globally.

Shlomo Lewkowicz

Shlomo Lewkowicz, D.Sc.

Co-Founder & CEO

40+ years of pioneering experience in medical device development, specialized in GI innovations. Deep expertise translating complex technologies into clinical solutions – including as a co-founder and key contributor at Given Imaging (PillCam), GI-View, Check-Cap, and AMIT at Technion.

Given Imaging, GI-View, Check-Cap, Technion
Shai Assia

Shai Assia, M.Sc. & MBA

Co-Founder & CTO

18 years of experience developing multidisciplinary medical devices, delivery systems, and implantables. MIT LGO Fellow with a proven track record in bringing innovations to market across various medical applications at IOPtima, Novartis, MobileODT, Clexio, and Coramaze.

MIT, Novartis, IOPtima, MobileODT, Clexio, Coramaze

Scientific Advisory Board

Prof. Anastasios Koulaouzidis, MD DM PhD FESGEInternational authority in capsule endoscopy and GI diagnostics; Clinical Professor, University of Southern Denmark & Odense University Hospital
Dr. Idit Dotan, MDEndocrinologist and Head of the Diabetes Unit, Rabin Medical Center; Director of multidisciplinary obesity and metabolic care center
Prof. Ram Weiss, MD PhDPediatric endocrinologist specializing in diabetes and obesity; Chief of Pediatrics, Rambam Medical Center; Professor, Technion Faculty of Medicine
Dr. Thomas Bjorsum-Meyer, MD PhDColorectal surgeon and clinical researcher in GI diagnostics and minimally invasive procedures, Odense University Hospital
Partner With Us

Building the Standard Measurement Layer for
Metabolic & GI Care

We are seeking strategic investors and clinical partners to advance the next phase of development.

© 2026 GastricTime Ltd. All rights reserved.

US Provisional Patent No. 63/837,170